BRPI0807487A8 - Uso de antagonistas de il-23 para o tratamento de infecção - Google Patents
Uso de antagonistas de il-23 para o tratamento de infecçãoInfo
- Publication number
- BRPI0807487A8 BRPI0807487A8 BRPI0807487A BRPI0807487A BRPI0807487A8 BR PI0807487 A8 BRPI0807487 A8 BR PI0807487A8 BR PI0807487 A BRPI0807487 A BR PI0807487A BR PI0807487 A BRPI0807487 A BR PI0807487A BR PI0807487 A8 BRPI0807487 A8 BR PI0807487A8
- Authority
- BR
- Brazil
- Prior art keywords
- antagonists
- treatment
- infection
- infections
- viral
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Abstract
USOS DE ANTAGONISTAS DE IL-23, KIT E COMPOSIÇÃO FARMACÊUTICA OU ESTÉRIL. A presente invenção refere-se a métodos e composições compreendendo antagonistas de IL-23 para o tratamento de infecções, tais como infecções crônicas bacterianas, virais e fúngicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88947507P | 2007-02-12 | 2007-02-12 | |
PCT/US2008/001717 WO2008153610A2 (en) | 2007-02-12 | 2008-02-08 | Use of il-23 antagonists for treatment of infection |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0807487A2 BRPI0807487A2 (pt) | 2015-09-01 |
BRPI0807487A8 true BRPI0807487A8 (pt) | 2016-02-10 |
Family
ID=40130357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0807487A BRPI0807487A8 (pt) | 2007-02-12 | 2008-02-08 | Uso de antagonistas de il-23 para o tratamento de infecção |
Country Status (13)
Country | Link |
---|---|
US (2) | US8586035B2 (pt) |
EP (1) | EP2064246B1 (pt) |
JP (2) | JP5320301B2 (pt) |
CN (1) | CN101668775B (pt) |
AU (1) | AU2008262544B2 (pt) |
BR (1) | BRPI0807487A8 (pt) |
CA (1) | CA2677835A1 (pt) |
CL (1) | CL2008000418A1 (pt) |
MX (1) | MX2009008617A (pt) |
NZ (2) | NZ578955A (pt) |
TW (1) | TWI426918B (pt) |
WO (1) | WO2008153610A2 (pt) |
ZA (1) | ZA200906126B (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI426918B (zh) * | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
EP2254998B1 (en) * | 2008-02-28 | 2015-12-23 | Argos Therapeutics, Inc. | Transient expression of immunomodulatory polypeptides for the prevention and treatment of autoimmune disease, allergy and transplant rejection |
US20110158992A1 (en) * | 2008-08-27 | 2011-06-30 | Schering Corporation | Engineered Anti-IL-23R Antibodies |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
EP3456740A1 (en) | 2010-11-04 | 2019-03-20 | Boehringer Ingelheim International GmbH | Anti-il-23 antibodies |
CA2822775A1 (en) * | 2011-01-04 | 2012-07-12 | Charite Universitatsmedizin Berlin | Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
UY34401A (es) | 2011-10-21 | 2013-05-31 | Abbvie Inc | Métodos para el tratamiento de hcv |
DE202012012956U1 (de) | 2011-10-21 | 2014-10-16 | Abbvie Inc. | Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US11078265B2 (en) | 2012-05-03 | 2021-08-03 | Boehringer Ingelheim International Gmbh | Anti-IL-23 antibodies |
US9803010B2 (en) | 2012-06-27 | 2017-10-31 | Merck Sharp & Dohme Corp. | Crystalline anti-human IL-23p19 antibodies |
UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
US10406218B2 (en) * | 2014-04-09 | 2019-09-10 | La Jolla Institute For Allergy And Immunology | Specific and unique T cell responses and molecular signatures for the treatment and diagnosis of Mycobacterium tuberculosis |
JP2017524359A (ja) | 2014-07-24 | 2017-08-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Il−23a関連疾患の処置に有用なバイオマーカー |
EA039598B9 (ru) | 2014-09-03 | 2022-03-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединение, нацеленное на ил-23а и фно-альфа, и его применение |
CN105420238A (zh) * | 2015-09-08 | 2016-03-23 | 中国农业科学院兰州兽医研究所 | 靶向抑制小鼠白细胞介素17A基因的序列siRNA-136 |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
WO2018067520A2 (en) * | 2016-10-04 | 2018-04-12 | Pop Test Oncology Llc | Therapeutic agents and methods: |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
SG11201909955XA (en) | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies |
US20200197389A1 (en) * | 2017-05-12 | 2020-06-25 | The Regents Of The University Of California | Methods for detecting dysbiosis and treating subjects with dysbiosis |
CN108743603B (zh) * | 2018-06-22 | 2020-06-30 | 山东省千佛山医院 | 利巴韦林单用或联合氟康唑的抗真菌产品及其应用 |
WO2020096058A1 (ja) * | 2018-11-09 | 2020-05-14 | 学校法人立命館 | 皮脂腺調整剤 |
CN112500490B (zh) * | 2020-10-14 | 2022-05-03 | 华南农业大学 | 一种抗左旋氧氟沙星抗体的F(ab)2片段及其制备方法和应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4144346A (en) | 1977-01-31 | 1979-03-13 | Janssen Pharmaceutica N.V. | Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles |
US4267179A (en) | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
EP0069442B1 (en) | 1981-06-06 | 1985-02-20 | Pfizer Limited | Antifungal agents, processes for their preparation, and pharmaceutical compositions containing them |
AU721334B2 (en) | 1996-09-12 | 2000-06-29 | Merck Sharp & Dohme Corp. | Antifungal combination therapy |
PE20000183A1 (es) | 1997-07-25 | 2000-03-11 | Schering Corp | Citoquinas de mamiferos y reactivos relacionados |
US6492497B1 (en) * | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
DK1181366T4 (da) | 1999-06-01 | 2013-09-23 | Merck Sharp & Dohme | Mammale receptorproteiner, beslægtede reagenser og fremgangsmåder |
ES2300276T5 (es) | 1999-09-09 | 2017-06-02 | Merck Sharp & Dohme Corp. | P40 de interleuquina-12 de mamífero e interleuquina B30. Sus combinaciones. Anticuerpos. Usos en composiciones farmacéuticas |
ES2307618T3 (es) | 2000-05-10 | 2008-12-01 | Schering Corporation | Proteinas subunidades de receptores de cotocinas de mamiferos, reactivos y metodos relacionados. |
AUPR381601A0 (en) * | 2001-03-19 | 2001-04-12 | Monash University | Method of treating respiratory conditions |
EP1418936A2 (en) * | 2001-05-09 | 2004-05-19 | Alk-Abell A/S | Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio. |
CA2501786C (en) * | 2002-10-30 | 2015-02-17 | Genentech, Inc. | Inhibition of il-17 production |
TWI357336B (en) * | 2003-03-10 | 2012-02-01 | Schering Corp | Uses of il-23 agonists and antagonists; related re |
EP1617805A4 (en) * | 2003-04-11 | 2012-07-04 | Medimmune Llc | METHODS FOR PREVENTING OR TREATING RESPIRATORY CONDITIONS |
AU2004239288B2 (en) | 2003-05-09 | 2010-01-28 | Centocor, Inc. | IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses |
KR100945327B1 (ko) * | 2003-07-08 | 2010-03-08 | 제넨테크, 인크. | Il-17a/f 이종 폴리펩티드 및 그의 치료 용도 |
GB0329146D0 (en) | 2003-12-16 | 2004-01-21 | Glaxosmithkline Biolog Sa | Vaccine |
CN1942201B (zh) * | 2004-02-17 | 2012-06-20 | 先灵公司 | 调节il-23活性的方法;相关试剂 |
US20060193821A1 (en) | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
GB0507561D0 (en) | 2005-04-14 | 2005-05-18 | Trinity College Dublin | Modulation of an immune response by filamentous haemagglutinin |
HUE042561T2 (hu) * | 2005-06-30 | 2019-07-29 | Janssen Biotech Inc | Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások |
CA2619052A1 (en) * | 2005-08-25 | 2007-03-01 | Eli Lily And Company | Anti-il-23 antibiodies |
EP3190125A1 (en) | 2005-08-31 | 2017-07-12 | Merck Sharp & Dohme Corp. | Engineered anti-il-23 antibodies |
DK3219328T3 (da) | 2005-12-29 | 2020-07-13 | Janssen Biotech Inc | Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser |
JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス, インコーポレイテッド | Il−17およびil−23アンタゴニストならびにその使用方法 |
KR101218484B1 (ko) | 2006-08-11 | 2013-01-04 | 머크 샤프 앤드 돔 코포레이션 | Il-17a에 대한 항체 |
TWI426918B (zh) * | 2007-02-12 | 2014-02-21 | Merck Sharp & Dohme | Il-23拮抗劑於治療感染之用途 |
SG178804A1 (en) | 2007-02-23 | 2012-03-29 | Schering Corp | Engineered anti-il-23p19 antibodies |
EP2059534B1 (en) | 2007-02-23 | 2012-04-25 | Schering Corporation | Engineered anti-il-23p19 antibodies |
NZ579251A (en) | 2007-02-28 | 2012-06-29 | Schering Corp | Engineered anti-il-23r antibodies |
US20110158992A1 (en) | 2008-08-27 | 2011-06-30 | Schering Corporation | Engineered Anti-IL-23R Antibodies |
-
2008
- 2008-02-05 TW TW097104700A patent/TWI426918B/zh not_active IP Right Cessation
- 2008-02-08 AU AU2008262544A patent/AU2008262544B2/en not_active Ceased
- 2008-02-08 EP EP08714214.7A patent/EP2064246B1/en active Active
- 2008-02-08 US US12/525,003 patent/US8586035B2/en not_active Expired - Fee Related
- 2008-02-08 MX MX2009008617A patent/MX2009008617A/es active IP Right Grant
- 2008-02-08 WO PCT/US2008/001717 patent/WO2008153610A2/en active Application Filing
- 2008-02-08 NZ NZ578955A patent/NZ578955A/en not_active IP Right Cessation
- 2008-02-08 CL CL2008000418A patent/CL2008000418A1/es unknown
- 2008-02-08 JP JP2009549119A patent/JP5320301B2/ja not_active Expired - Fee Related
- 2008-02-08 CA CA002677835A patent/CA2677835A1/en not_active Abandoned
- 2008-02-08 BR BRPI0807487A patent/BRPI0807487A8/pt not_active IP Right Cessation
- 2008-02-08 NZ NZ599827A patent/NZ599827A/xx not_active IP Right Cessation
- 2008-02-08 CN CN200880010208.4A patent/CN101668775B/zh not_active Expired - Fee Related
-
2009
- 2009-09-03 ZA ZA200906126A patent/ZA200906126B/xx unknown
-
2012
- 2012-10-18 JP JP2012230578A patent/JP2013014624A/ja active Pending
-
2013
- 2013-10-28 US US14/065,171 patent/US20140147442A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP5320301B2 (ja) | 2013-10-23 |
JP2013014624A (ja) | 2013-01-24 |
AU2008262544B2 (en) | 2014-01-16 |
US8586035B2 (en) | 2013-11-19 |
US20140147442A1 (en) | 2014-05-29 |
EP2064246A2 (en) | 2009-06-03 |
CA2677835A1 (en) | 2008-12-18 |
NZ578955A (en) | 2012-06-29 |
CN101668775B (zh) | 2014-05-07 |
US20100291084A1 (en) | 2010-11-18 |
MX2009008617A (es) | 2009-10-14 |
WO2008153610A2 (en) | 2008-12-18 |
BRPI0807487A2 (pt) | 2015-09-01 |
WO2008153610A3 (en) | 2009-03-19 |
CL2008000418A1 (es) | 2008-11-14 |
TW200902062A (en) | 2009-01-16 |
CN101668775A (zh) | 2010-03-10 |
JP2010518087A (ja) | 2010-05-27 |
NZ599827A (en) | 2013-11-29 |
ZA200906126B (en) | 2010-06-30 |
TWI426918B (zh) | 2014-02-21 |
EP2064246B1 (en) | 2013-05-22 |
AU2008262544A1 (en) | 2008-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0807487A8 (pt) | Uso de antagonistas de il-23 para o tratamento de infecção | |
BR112013025987A2 (pt) | derivados de pirimidina para o tratamento de infecções virais | |
CL2008001855A1 (es) | Compuestos ciclicos condensados derivados del boro; composicion farmaceutica; y uso en el tratamiento y/o prevencion de una enfermedad infecciosa. | |
CL2009000426A1 (es) | Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas | |
NI201000044A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
BRPI0922220B8 (pt) | uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos | |
BRPI0815920A2 (pt) | Composto, composição farmacêutica, e, uso do composto. | |
BR112014021531A8 (pt) | composto, composição farmacêutica e usos dos mesmos | |
HN2011003011A (es) | Composiciones sublinguales de dexmedetomidina y metodos de uso de ellas | |
CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
MX2015015506A (es) | Peptidos antimicrobianos. | |
BR112012017473A2 (pt) | pirido(1,2-a) pirimidinas, seu uso, bem como composição farmacêutica compreendendo tais compostos | |
CL2008001740A1 (es) | Compuestos derivados de piperidinas sustituidas, inhibidores de la dna-girasa y/o topoisomerasa iv; procedimeinto para su preparacion; composiicon farmaceutica que comprende estos compustos y su uso en el tratamiento de una infeccion bacteriana. | |
NI201000015A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
BR112016016854A2 (pt) | Derivados de 7-oxo-1,6-diazabiciclo[3.2.1]octana, seu processo de preparação e seu uso, composição farmacêutica e seu uso pedidos de patente relacionados | |
CL2009001345A1 (es) | Compuestos derivados de 1-piridin-2-il-urea y 1-pirimidin-2-il-urea sustituidos, inhibidores de adn girasa y topoisomerasa iv; composicion farmaceutica; y su uso en tratamiento de infecciones bacterianas como neumonia adquirida intrahospitalariamente, infecciones a la piel, bronquitis, sinusitis, entre otras enfermedades. | |
BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
BR112016022722B8 (pt) | Composto, composição farmacêutica que o comprende e uso do mesmo | |
CL2012001757A1 (es) | Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas. | |
CL2007001542A1 (es) | Compuestos derivados de aminotiazoles, composicion farmaceutica; y uso para el tratamiento de infecciones bacterianas. | |
AR053775A1 (es) | Nonadepsipeptidos acilados ii | |
BR112016013600A2 (pt) | Peptídeo antimicrobiano e seus usos | |
ATE524488T1 (de) | Lysobactinamide | |
BR112014016804A2 (pt) | composições, métodos de uso e métodos de tratamento | |
CL2011002967A1 (es) | Compuestos derivados de 3-oxadiazolil-5-fenil-piperidina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamient y/o profilaxis de trastornos cardiovasculares, tromboembolicos y tumorales. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
B25G | Requested change of headquarter approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |